Publications by authors named "Bill Cavanagh"

Claim this Profile
R
Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial.
Bill Cavanagh, Paul J Gomes, Christopher E Starr, Kelly K Nichols, Todd C Brady

Ophthalmol Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.
David Clark, Bill Cavanagh, Alan L Shields, Paul Karpecki, John Sheppard

Am J Ophthalmol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.
David McMullin, David Clark, Bill Cavanagh, Paul Karpecki, Todd C Brady

Clin Ophthalmol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis